Exicure Inc. (XCUR) Names James Sulat to Board
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/22/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- One killed, three injured when man attacks Swedish school with sword
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
Exicure Announces Appointment of James Sulat to Board of Directors
January 5, 2021 7:00 AM ESTCHICAGO & CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Exicure, Inc. (NASDAQ: XCUR), a pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA) technology, today announced the appointment of James Sulat to its Board of Directors.
James Jim Sulat joins Exicure after decades of experience advising and leading biopharmaceutical companies, including serving in the roles of President, Chief Executive Officer and Chief Financial Officer at various companies. Mr. Sulat currently serves on the boards of directors of Valneva SE and Arch Therapeutics and... More
